Single Dose Escalations Study of Amphotericin B Colloidal Dispersion In Healthy Subjects in China

Exclusion Criteria

• •History of allergy or hypersensitivity.
• •Presence of any acute or chronic medical condition within 3 months prior to investigational products administration, including but not limited to: hepatic, gastrointestinal, renal, hematologic (including coagulation), pulmonary, neurologic, respiratory, endocrine, or cardiovascular system abnormalities; psychiatrical disease including major psychiatric disorders (e.g., schizophrenia, bipolar disorder); acute infection; or other conditions that would interfere with the absorption, distribution, metabolism, or excretion of drugs.
• •During the screening period, abnormal and clinically significant of physical examination, vital signs, laboratory examination, etc.
• •A positive result in hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), anti-hepatitis C virus (HCV) antibodies, a syphilis test, or an human immunodeficiency virus (HIV) test.
• •Lost blood or donated more than 400 mL of blood within 3 months prior to the screening.
• •Participation in a clinical drug study 30 days prior to present study.
• •Use of any other drugs within 2 weeks prior to the screening.
• •Subjects planning to give birth or donate sperm during the study or within 3 months after the study.
• •The partner of the subject is unwilling to take effective contraceptive measures.
• •Other unfavorable factors diagnosed by investigators.